Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unkno...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, Cyrille Hulin, Gerald Marit, Xavier Leleu, Lionel Karlin, Murielle Roussel, Anne-Marie Stoppa, Francois Guilhot, Thierry Lamy, Laurent Garderet, Brigitte Pegourie, Mamoun Dib, Catherine Sebban, Pascal Lenain, Sabine Brechignac, Bruno Royer, Marc Wetterwald, Laurence Legros, Frédérique Orsini-Piocelle, Laurent Voillat, Xavier Delbrel, Denis Caillot, Margaret Macro, Thierry Facon, Michel Attal, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Ferrata Storti Foundation 2014-07-01
Σειρά:	Haematologica
Διαθέσιμο Online:	https://haematologica.org/article/view/7089
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!